With the debate swirling around the efficacy and safety of UV-C technology, an individual needs which generation the product is. Infection Control Today® continues its ongoing special reporting on UV-C technology.
Even though the germicidal effects of ultraviolet light were first discovered in 1877, currently in the health care industry, a debate of the efficacy of ultraviolet-C light (UV-C) technology continues. Also, with some investigators publishing studies showing it is safe and others not, the question comes down to which company’s technology works and what does not. Are the studies the companies are using their own, done by an independent research firm, or are the companies using competitors’ data? What generation of UV-C technology are the investigators using?
In the second of 2 segments of this exclusive Infection Control Today® (ICT®) interview with Gunner Lyslo, founder and CEO of Surfacide, continues the discussion on where the industry is going and what questions for health care facilities, schools, businesses, and others should ask when they are looking for UVC technology to keep their employees and visitors safe.
Although, UV-C has been proven to be effectual against SARS-CoV-2, some individuals still are hesitant to consider UV-C technology. Lyslo pushes back and says that second generation technology (like Surfacide) demonstrates that the technology is effective.
“It's an incredibly important technology [and] disinfection modality. And if used in an evidence-based way, with the proper indications for use, it will have a tremendous impact to the benefit of all those end users and all those individuals who are entering those spaces. [This is true] whether it would be a hospital, which hospitals are still first and foremost to [Surfacide], because that's where you're dealing with an immunocompromised patient population, as well as you're dealing with an environmental services team are frontline health care workers who have numerous workplace stresses.”
The first part of the interview with Lyslo is here.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.
Managing Multimorbidity and Polypharmacy in HIV: Insights From Michelle S. Cespedes, MD, MS
November 20th 2024Michelle S. Cespedes, MD, MS, discusses the challenges of managing multimorbidity and polypharmacy in HIV treatment, emphasizing patient education, evolving guidelines, and real-world insights from the REPRIEVE study.
Longhorn Vaccines and Diagnostics to Showcase Breakthrough Vaccine Data at IDWeek 2024
November 19th 2024Longhorn Vaccines and Diagnostics revealed promising data on universal influenza vaccine LHNVD-110 and AMR sepsis vaccine LHNVD-303 at IDWeek 2024, addressing critical global health challenges.
Infection Intel: Revolutionizing Ultrasound Probe Disinfection With Germitec's Chronos
November 19th 2024Learn how Germitec’s Chronos uses patented UV-C technology for high-level disinfection of ultrasound probes in 90 seconds, enhancing infection control, patient safety, and environmental sustainability.
CDC HICPAC Considers New Airborne Pathogen Guidelines Amid Growing Concerns
November 18th 2024The CDC HICPAC discussed updates to airborne pathogen guidelines, emphasizing the need for masks in health care. Despite risks, the committee resisted universal masking, highlighting other mitigation strategies